Neuroscience

Luxury Hotel Innovates Wellness Tourism with Global-First Sleep Enhancement Offering

First-of-its-kind partnership between InterContinental Singapore and NuCalm brings cutting edge restorative travel to luxury travelers LOS ANGELES, Aug. 8, 2025 /PRNewswire/…

4 months ago

10x Genomics Reports Second Quarter 2025 Financial Results

PLEASANTON, Calif., Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology,…

4 months ago

10x Genomics to Acquire Scale Biosciences

Acquisition Will Further Expand Chromium's Capabilities PLEASANTON, Calif., Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in…

4 months ago

Creyos Expands Session Notes to Turn Cognitive Health Testing Into Timely Clinical Action

Developed by world-renowned neuroscientist Professor Adrian Owen, Creyos helps providers detect cognitive impairment through a scientifically validated brain health assessment platform…

4 months ago

The Dr. Gundry Podcast, Hosted by Dr. Steven Gundry, Surpasses One Million Subscribers on YouTube

Known for Gut Health Insights, Olive Oil Advocacy, and Myth-Busting Advice, The Dr. Gundry Podcast Has Surpassed One Million Subscribers…

4 months ago

Corporate Update, August 2025

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ: PBM) Dear Shareholders, Thank…

5 months ago

Xenon to Report Q2 2025 Financial Results on August 11, 2025

VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company…

5 months ago

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery…

5 months ago

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery…

5 months ago